Clinical Trials Directory

Trials / Completed

CompletedNCT01656057

The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Filip Krag Knop · Academic / Other
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but also modulates the energy expenditure in (brown) adipose tissue and muscle tissue. This action is due to stimulation of the receptor TGR5 by bile acids. Recently scientists have discovered that this receptor in rodents is also expressed on the surface of intestinal L-cells (which normally secrets Glucagon-Like Peptide-1 (GLP-1) in response to nutrient stimulation). The stimulation of this receptor has shown a GLP-1 secretion from the intestinal cells which is interesting since GLP-1 has a central role in maintaining normal glucose tolerance and thus blood sugar. Given the above, bile acids has an important impact on intestinal GLP-1 secretion. Whether these scientific findings can be proven in human beings is uncertain. The primary hypothesis is that stimulating gall bladder emptying via Cholecystokinin (CCK) in healthy subjects will result in a significant GLP-1 response. We also hypothesize that adding orally Metformin or a sequestrant ("a bile acid binder") will further enhance this GLP-1 response.

Conditions

Interventions

TypeNameDescription
DRUGAcetaminophenAcetaminophen dissolved in 50 ml of water
DRUGMetforminMetformin + acetaminophen dissolved in 50 ml of water
DRUGColesevelamColesevelam + acetaminophen dissolved in 50 ml of water
OTHERCholecystokinin-8iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
OTHERSalineiv. saline infusion 40 ml/hour for the first 60 minutes

Timeline

Start date
2012-07-01
Primary completion
2013-10-01
Completion
2014-04-01
First posted
2012-08-02
Last updated
2015-07-14

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01656057. Inclusion in this directory is not an endorsement.